08:34 AM EDT, 09/09/2025 (MT Newswires) -- Jazz Pharmaceuticals ( JAZZ ) said Tuesday its drug Modeyso has been included in the National Comprehensive Cancer Network's oncology guidelines as a treatment option for pediatric and adult patients with recurrent or progressive mutant diffuse glioma.

The drug received accelerated approval from the US Food and Drug Administration in August for patients aged one and older with progressive disease following prior therapy, the company said.

The rapid addition of Modeyso to the NCCN guidelines reflects "the urgency of the unmet need" for treatments for this aggressive brain tumor, Jazz Pharmaceuticals ( JAZZ ) said.

Modeyso's FDA approval was supported by data from 50 patients showing a 22% response rate and a median duration of response of 10.3 months, the company said.